Last reviewed · How we verify

NCT05632549

The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma

Status unknown Phase 3 Last updated 30 November 2022
What this trial tests

Phase 3 trial testing Placebo in Moderate Persistent Asthma in 66 participants. Status unknown.

Timeline
8 August 2022
Primary endpoint
8 August 2024
8 August 2024

Quick facts

Lead sponsorTanta University
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment66
Start date8 August 2022
Primary completion8 August 2024
Estimated completion8 August 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 8 to 18, any sex, with Moderate Persistent Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children with Moderate Persistent Asthma

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. L-Carnitine and Biotin as Adjunctive Therapies in Children with Moderate Persistent Asthma: A Randomized Placebo controlled Study
    Khedr MO, El-Haggar SM, El-Razik AMA, elmeazawy RZ, et al · · 2026 · DOI 10.21203/rs.3.rs-9272063/v1

Verify or expand the search:

Other trials of L-Carnitine 500Mg Oral Tablet

Trials testing the same drug.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05632549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing